Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitu...
Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Abstract Aims Canagliflozin, a sodium glucose co-transporter 2 inhibitor, has demonstrated glycemic improvements across studies of patients with type 2 diabetes mellitus (T2DM). The impact of canagliflozin on HbA1c lowering was assessed by baseline HbA1c and known duration of T2DM. Methods This post hoc analysis pooled data from patients with T2DM...
Alternative Titles
Full title
Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1827923297
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1827923297
Other Identifiers
ISSN
1056-8727
E-ISSN
1873-460X
DOI
10.1016/j.jdiacomp.2014.12.016
